Schistosomes: challenges in compound screening.

Area of Science:

• Parasitology
• Drug Discovery
• Tropical Diseases

Background:

• Schistosome biology research advanced with in vivo and in vitro cultivation techniques.
• Understanding parasite mechanisms aids in identifying diagnostic, immunological, and chemotherapeutic targets.
• Praziquantel is the primary schistosomiasis treatment, but parasite resistance is a growing concern.

Purpose of the Study:

• To review current in vitro and in vivo drug screening strategies for schistosomes.
• To highlight best practices for compound screening in TDR-designated centers.
• To detail challenges in schistosome drug screening.

Main Methods:

• Review of existing literature on schistosome drug screening.
• Analysis of in vitro and in vivo screening methodologies.
• Examination of best practices and challenges in compound screening.

Main Results:

• Established in vitro and in vivo culture systems facilitate parasite biology studies.
• Praziquantel resistance necessitates the development of new anti-schistosome drugs.
• Effective drug discovery requires integrated chemical synthesis, lead optimization, and screening strategies.

Conclusions:

• New drug discovery for schistosomiasis is urgently needed.
• Robust in vitro and in vivo screening platforms are essential for identifying novel drug candidates.
• Addressing challenges in screening methodologies will accelerate the development of effective treatments.